COO

Business Context and Reporting Period

Company: The Cooper Companies, Inc. (COO)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended April 30, 2026
Business Overview: The Company operates through two segments: CooperVision (contact lenses) and CooperSurgical (fertility and women's health care). The Company is a large accelerated filer with 195.0 million shares outstanding as of June 1, 2026.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 7.9% in Q2 2026 and 7.0% for the six-month period compared to the prior year, driven by growth in both CooperVision (8%) and CooperSurgical (8%) segments. Favorable foreign exchange rates contributed approximately $28.4 million to Q2 sales.
• Profitability Decline: Operating income swung from a profit of $184.8 million in Q2 2025 to a loss of $31.0 million in Q2 2026. This was primarily due to a $271.6 million litigation expense (net of insurance) recorded in the CooperSurgical segment.
• SG&A Expenses: Selling, general, and administrative expenses surged 69% in Q2 2026 ($676.2 million vs. $399.0 million) due to the litigation accrual. Excluding this item, SGA expenses were relatively stable or decreased slightly.
• Segment Performance: CooperVision operating income increased 16% to $215.6 million. CooperSurgical reported an operating loss of $225.0 million compared to income of $23.7 million in the prior year.
• Debt Structure: Short-term debt increased significantly to $598.9 million from $47.8 million at the prior fiscal year-end, while long-term debt decreased to $1,861.3 million from $2,457.5 million. The Company extended the maturity of $950 million of term loans to 2031.

Guidance, Outlook, Risks, and Unusual Items

• Unusual Item (Litigation): The Company recorded a $271.6 million charge related to the LifeGlobal embryo culture media recall. This consisted of a $324.1 million accrued liability partially offset by $52.5 million in insurance recoveries. As of June 5, 2026, over 1,500 claimants have been proffered, and more than 140 lawsuits have been filed.
• Outlook: Management remains optimistic about long-term prospects for contact lens and healthcare markets but cites risks including global economic conditions, tariffs, and supply chain disruptions. No specific numerical guidance for future periods was provided in this text.
• Risks:
  • Legal: Ongoing appeal of a U.K. First-tier Tribunal decision regarding payroll taxes on the 2014 Sauflon acquisition, with a potential loss range of £0 to £71.7 million.
  • Market: Exposure to foreign currency fluctuations and interest rate changes on variable-rate debt.
  • Operational: Risks related to product recalls, regulatory approvals, and cybersecurity.
• Liquidity: The Company maintains $1,383.0 million in available capacity under its revolving credit facility and believes current cash and operating cash flows are sufficient for the next 12 months.

Investor Verification Checklist

• Litigation Exposure: Verify the status of the LifeGlobal recall lawsuits and the potential for losses exceeding the current $324.1 million accrual.
• UK Tax Dispute: Monitor the appeal process regarding the Sauflon Group payroll tax matter and the potential impact of the £71.7 million exposure.
• Debt Covenants: Confirm continued compliance with Total Leverage and Interest Coverage ratios given the recent restructuring of term loans.
• Share Repurchases: Track the remaining $860.8 million authorization under the share repurchase program and the pace of buybacks.
• Segment Margins: Analyze CooperVision's margin expansion versus CooperSurgical's margin compression to understand the underlying business health excluding the litigation charge.